Verastem To Participate In Panel At The MassBio Patient Advocacy Summit

Verastem, Inc. VSTM, focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced today that Robert Forrester, Verastem President and Chief Executive Officer, will participate in a panel titled, “Live & Breathe: Building a Patient-Centered Biotech,” at the MassBio Patient Advocacy Summit on November 10, 2014 at 8:45 am ET at the Genzyme Center in Cambridge, MA. “Improving patient care is at the core of what we aim to accomplish,” said Mr. Forrester. “We want to change the way cancer is treated and improve patient outcomes through the targeted killing of cancer stem cells. Engaging with patients and patient advocates early in the development process is critical to fully understanding the unmet needs that exist with currently available therapies. At Verastem, we have partnered with mesothelioma advocates worldwide and their experience has shaped our development programs and helped us to keep enrollment of our registration-directed study, COMMAND, on track. We are driven and passionate about the work we do because it gives hope to patients who have been diagnosed with cancer.” At the MassBio Patient Advocacy Summit, industry leaders, patient advocates and other stakeholders are gathering to examine ways in which life sciences companies can more fully incorporate the patient voice into the work they do—not just approaching regulatory applications or at commercialization, but throughout the drug development cycle.